Skip to main content

TRV GP VI, LLC

13F filer · CIK 0001990716
Reported Aug 10, 2026
Net buyer this quarter
13F portfolio value$232MU.S. long equity reported on 13F
Positions41 new · 0 closed
Net flow last quarter+$44.8MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 10, 20264 positions
SEPNSepterna, Inc.$141M60.72%9.22%Not reportedQ4 2024
SPTXSeaport Therapeutics, Inc.$44.8M19.27%3.85%NewQ2 2026
RAPPRapport Therapeutics, Inc.$40.4M17.39%2.02%Not reportedQ4 2024
TNGXTango Therapeutics, Inc.$6.07M2.61%0.12%Not reportedQ4 2024
Q1 2026Reported May 7, 20263 positions
SEPNSepterna, Inc.$101M74.64%9.38%Not reportedQ4 2024
RAPPRapport Therapeutics, Inc.$30.3M22.37%2.03%Not reportedQ4 2024
TNGXTango Therapeutics, Inc.$4.06M3.00%0.13%Not reportedQ4 2024
Q4 2025Reported Feb 13, 20263 positions
SEPNSepterna, Inc.$117M79.05%9.40%Not reportedQ4 2024
RAPPRapport Therapeutics, Inc.$29.4M19.80%2.03%Not reportedQ4 2024
TNGXTango Therapeutics, Inc.$1.72M1.16%0.14%Not reportedQ4 2024
Q3 2025Reported Nov 13, 20253 positions
SEPNSepterna, Inc.$79.2M72.26%9.44%Not reportedQ4 2024
RAPPRapport Therapeutics, Inc.$28.8M26.26%2.03%Not reportedQ4 2024
TNGXTango Therapeutics, Inc.$1.63M1.49%0.17%Not reportedQ4 2024
Premium opens every quarter this fund has filed
SpoorBase

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.